Company Overview and News

 
Mid and small cap: Tech, pharma, consumer stocks top performers while majority of stocks trade in red

2018-10-17 financialexpress
While 90% of Nifty small-cap and 77% of Nifty mid-cap stocks have been trading in the red since the beginning of the year, some stocks from export-driven and consumer sector have given returns up to 89.26% in the small and mid cap space. However, this calender year, Nifty Midcap 100 and Nifty Small Cap 100 index has yielded a negative returns of 20.6% and 33.2% respectively.
500408 IDBLZ 532960 532541 MS 500031 500252 509488 NIITTECH GRAPHITE IBVENTURES HEXAWARE STRTECH 532129 LAXMIMACH SRLRY 532374 TATAELXSI BAJAJELEC

 
Hexaware Technologies Limited - Allotment of ESOP/ESPS

2018-10-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HEXAWARE 532129

 
Hexaware Technologies Limited - ESOP/ESOS/ESPS

2018-10-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HEXAWARE 532129

 
Hexaware Technologies Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-10-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HEXAWARE 532129

 
Weak rupee boosts IT space, stocks soar to 52-week highs

2018-09-17 moneycontrol
Share price of several medium and large information technology (IT) stocks are trading higher in the today's trading session on the back of weakness in rupee continues as it falls over 1 percent in the early trade on Monday.
532221 532892 SONATSOFTW HCLTECH HCTHY MOTILALOFS 532281 HEXAWARE 532129

 
Investec looks to expand investment banking, lending operations in India

2018-08-28 livemint
Mumbai: Investec is looking to expand its investment banking services in India and add a lending business to its operations in the country, a top company executive said.
ASAL HEXAWARE 532129

 
Hexaware stock plunges on stake sale

2018-08-24 thehindubusinessline
On Friday, the stock of Hexaware Technologies started the session with a huge gap-down opening at ₹453 and extended its fall to ₹415.2. The volume traded was extraordinary. Following some intra-day recovery, the stock closed at ₹431.5 on the BSE with a loss of 13 per cent. This selling was on reports of a private equity investor selling stake. The fall has breached a key support at ₹450. Next supports are at ₹415 and ₹390.
HEXAWARE 532129

 
Baring PE Asia sells over 8% stake of Hexaware Tech for Rs 1,120 crore

2018-08-24 moneycontrol
Baring PE Asia today sold over 8 per cent stake in IT firm Hexaware Technologies for nearly Rs 1,120 crore through an open market transaction. The shares were disposed of by the private equity firm through HT Global IT Solutions Holdings, an investment vehicle through which Baring Asia holds a controlling stake in Hexaware.
SCGLF SCGLY GLE HEXAWARE 532129

 
An evening walk down Dalal Street | Nifty gives up 11,600, but indices end week with positive gains

2018-08-24 moneycontrol
Amid sombre global cues along with a weaker rupee back home, equity benchmarks managed to end the week on a negative note. The Nifty closed around 11,550-mark, while the Sensex saw cuts of almost quarter of a percent.
AXBKY YESBANK AXBA RCOM AXB AXISBANK 532648 YYBKY HEXAWARE 532712 532129 532215

 
Hexaware Technologies crashes 19%

2018-08-24 thehindubusinessline
Shares of Hexaware Technologies slumped as much as 19 per cent in the morning trade on reports that Baring PE Asia is selling stake worth around Rs 1,100 crore.
HEXAWARE 532129

 
Hexaware tanks 17% as Baring PE likely to have sold 8.4% equity stake via block deals

2018-08-24 moneycontrol
Hexaware Technologies share price dropped as much as 16.6 percent in morning on Friday following likely dilution of stake by the promoter.
HEXAWARE 532129

 
Baring Private Equity Asia to sell Hexaware stake worth around Rs 1,100 crore

2018-08-24 livemint
Mumbai: Asia-focused private equity firm (PE) Baring Private Equity Asia is selling its stake worth almost Rs 1,120 crore in IT services company Hexaware Technologies Ltd, said a person aware of the development. Baring PE Asia currently holds a 71.25% stake in the IT company, through an entity called HT Global IT Solutions Holdings Ltd.
HEXAWARE 532129

 
Hexaware Technologies Limited - Press Release

2018-08-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HEXAWARE 532129

 
Hexaware Technologies Limited - Updates

2018-08-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HEXAWARE 532129

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...